EUVIMEDEUVIMED entdecken
Open Access

The TRaditional versus Early Aggressive Therapy for Multiple Sclerosis (TREAT-MS) trial: design and baseline characteristics of participants

Ellen M Mowry, Peiqing Qian, William Meador, Sharon Lynch, Ram Narayan, Aimee Borazanci, Derrick Robertson, Sara Qureshi, Jennifer Graves, Jason Silversteen, Megan Esch, Leticia Tornes und 24 weitere

Contemporary Clinical Trials · 2025-12 · 159 · 108117

DOI: 10.1016/j.cct.2025.108117 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Contemporary Clinical Trials, 2025-12. Verfasst von Ellen M Mowry und 35 weiteren Autor:innen. Beteiligte Einrichtung: Johns Hopkins University School of Medicine, Department of Neurology, 600 N. Wolfe Street, Baltimore, MD 21287, United States. Electronic address: em…. Hauptthemen laut MEDLINE: Multiple Sclerosis, Relapsing-Remitting. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 46 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NIBIB NIH HHS, Patient-Centered Outcomes Research Institute, National Multiple Sclerosis Society.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: Whether early use of higher-efficacy disease-modifying therapy (DMT) reduces later risk of disability in multiple sclerosis (MS) has not been studied as a prospective treatment strategy. Herein, we describe the TRaditional versus Early Aggressive Therapy for MS (TREAT-MS) trial design and provide the baseline characteristics of the enrolled population. METHODS: TREAT-MS is a pragmatic, randomized, rater-blinded trial of DMT strategies in treatment-naive people aged 18-60 years with relapsing-remitting MS (RRMS). Participants were randomized (1:1, stratified by site and long-term disability risk classification) to one of two treatment strategies: higher-efficacy or traditional DMT; the specific DMT within the assigned strategy was chosen by the clinician/patient pair. Participants could switch DMT for breakthrough disease occurring after 6 months on DMT. The primary outcome is sustained worsening of the Expanded Disability Status Scale (EDSS)-plus, a composite endpoint that includes the EDSS and the timed 25-ft walk and 9-hole peg tests. RESULTS: TREAT-MS includes 900 people with the following baseline characteristics: mean age 36 ± 10 years; 629 (70 %) female gender; 648 (72 %) white, 168 (19 %) Black/African American race, and 105 (12 %) Hispanic or Latino. Mean time since MS symptom onset was 2.6 (± 4.5) years, and mean EDSS score was 2.5 (± 1.3). CONCLUSION: TREAT-MS seeks to address how early DMT strategy influences MS disability and related outcomes. The results will be generalizable to future individuals newly diagnosed with RRMS who, with their clinicians, will be able to use them to make data-driven DMT decisions about how to maximize their intermediate-term function.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Multiple Sclerosis, Relapsing-RemittingHumansAdultFemaleMaleMiddle AgedYoung AdultAdolescentDisability EvaluationPragmatic Clinical Trials as TopicDisease ProgressionResearch DesignRandomized Controlled Trials as Topic

Stichwörter der Autor:innen

DisabilityDisease-modifying therapyMultiple sclerosisRandomized controlled trialTherapeutic strategy

Autor:innen und Institutionen

  • Johns Hopkins University School of Medicine, Department of Neurology, 600 N. Wolfe Street, Baltimore, MD 21287, United States. Electronic address: emowry1@jhmi.edu.
  • Swedish Neuroscience Institute, 1600 E Jefferson Street, Seattle, WA 98122, United States.
  • University of Alabama at Birmingham, Department of Neurology, 1720 7th Ave S, Birmingham, AL 35294, United States.
  • University of Kansas Medical Center, Department of Neurology, 3901 Rainbow Blvd, Kansas City, KS 66160, United States.
  • Barrow Neurological Institute, 240 W. Thomas Rd, Ste. 400, Phoenix, AZ 85013, United States.
  • University of South Florida, College of Medicine, Department of Neurology, 12901 Bruce B. Downs Blvd, MDC 55, Tampa, FL 33629, United States.

Förderung

  • NIBIB NIH HHS
  • Patient-Centered Outcomes Research Institute
  • National Multiple Sclerosis Society

Zitieren

APA

Mowry, E. M., Qian, P., Meador, W., Lynch, S., Narayan, R., Borazanci, A., Robertson, D., Qureshi, S., Graves, J., Silversteen, J., Esch, M., Tornes, L., Riley, C., Kaisey, M., Sicotte, N., Pawate, S., Gyang, T., Rempe, T., Obeidat, A. Z., …, & TREAT-MS Trial Team (2025). The TRaditional versus Early Aggressive Therapy for Multiple Sclerosis (TREAT-MS) trial: design and baseline characteristics of participants. Contemporary Clinical Trials, 159, 108117. https://doi.org/10.1016/j.cct.2025.108117

Vancouver

Mowry EM, Qian P, Meador W, Lynch S, Narayan R, Borazanci A, et al. The TRaditional versus Early Aggressive Therapy for Multiple Sclerosis (TREAT-MS) trial: design and baseline characteristics of participants. Contemporary Clinical Trials. 2025;159:108117. doi:10.1016/j.cct.2025.108117

BibTeX
@article{Mowry2025,
  author = {Mowry, Ellen M and Qian, Peiqing and Meador, William and Lynch, Sharon and Narayan, Ram and Borazanci, Aimee and Robertson, Derrick and Qureshi, Sara and Graves, Jennifer and Silversteen, Jason and Esch, Megan and Tornes, Leticia and Riley, Claire and Kaisey, Marwa and Sicotte, Nancy and Pawate, Siddharama and Gyang, Tirisham and Rempe, Torge and Obeidat, Ahmed Z and Ganesh, Geeta and Ryerson, Lana Zhovtis and Smith, Tyler and Rose, John and Carass, Aaron and Chalayon, Ornusa and Kruse-Hoyer, Mason and Salami, Monilola and Liu, Amy and Dewey, Blake and Chen, Jacob M and Ogburn, Elizabeth and Koch, Carolyn and Prince, Jerry and Cassard, Sandra D and Newsome, Scott D and TREAT-MS Trial Team, TREAT-MS Trial Team},
  title = {The TRaditional versus Early Aggressive Therapy for Multiple Sclerosis (TREAT-MS) trial: design and baseline characteristics of participants},
  journal = {Contemporary Clinical Trials},
  year = {2025},
  volume = {159},
  pages = {108117},
  doi = {10.1016/j.cct.2025.108117}
}
Kostenlos starten →